432 related articles for article (PubMed ID: 15888780)
1. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study.
Watabe H; Mitsushima T; Yamaji Y; Okamoto M; Wada R; Kokubo T; Doi H; Yoshida H; Kawabe T; Omata M
Gut; 2005 Jun; 54(6):764-8. PubMed ID: 15888780
[TBL] [Abstract][Full Text] [Related]
2. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
[TBL] [Abstract][Full Text] [Related]
3. Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study.
Ikeda F; Shikata K; Hata J; Fukuhara M; Hirakawa Y; Ohara T; Mukai N; Nagata M; Yoshida D; Yonemoto K; Esaki M; Kitazono T; Kiyohara Y; Ninomiya T
J Epidemiol; 2016 Dec; 26(12):629-636. PubMed ID: 27265836
[TBL] [Abstract][Full Text] [Related]
4. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis.
Watanabe M; Kato J; Inoue I; Yoshimura N; Yoshida T; Mukoubayashi C; Deguchi H; Enomoto S; Ueda K; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Tekeshita T; Mohara O; Ushijima T; Ichinose M
Int J Cancer; 2012 Dec; 131(11):2632-42. PubMed ID: 22383377
[TBL] [Abstract][Full Text] [Related]
5. Analysis of ABC (D) stratification for screening patients with gastric cancer.
Kudo T; Kakizaki S; Sohara N; Onozato Y; Okamura S; Inui Y; Mori M
World J Gastroenterol; 2011 Nov; 17(43):4793-8. PubMed ID: 22147980
[TBL] [Abstract][Full Text] [Related]
6. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm.
Choi HS; Lee SY; Kim JH; Sung IK; Park HS; Shim CS; Jin CJ
J Dig Dis; 2014 Jun; 15(6):293-8. PubMed ID: 24602176
[TBL] [Abstract][Full Text] [Related]
7. Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.
Kishikawa H; Kimura K; Ito A; Arahata K; Takarabe S; Kaida S; Miyauchi J; Miura S; Kanai T; Nishida J
Digestion; 2017; 95(3):229-236. PubMed ID: 28355604
[TBL] [Abstract][Full Text] [Related]
8. Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.
Song M; Camargo MC; Weinstein SJ; Murphy G; Freedman ND; Koshiol J; Stolzenberg-Solomon RZ; Abnet CC; Männistö S; Albanes D; Rabkin CS
Aliment Pharmacol Ther; 2018 Feb; 47(4):494-503. PubMed ID: 29243850
[TBL] [Abstract][Full Text] [Related]
9. Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects.
Yamaji Y; Mitsushima T; Ikuma H; Okamoto M; Yoshida H; Kawabe T; Shiratori Y; Saito K; Yokouchi K; Omata M
Gut; 2001 Sep; 49(3):335-40. PubMed ID: 11511553
[TBL] [Abstract][Full Text] [Related]
10. The new modified ABCD method for gastric neoplasm screening.
Park CH; Kim EH; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
Gastric Cancer; 2016 Jan; 19(1):128-35. PubMed ID: 25663259
[TBL] [Abstract][Full Text] [Related]
11. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.
Sasazuki S; Inoue M; Iwasaki M; Otani T; Yamamoto S; Ikeda S; Hanaoka T; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1341-7. PubMed ID: 16835334
[TBL] [Abstract][Full Text] [Related]
12. Fasting gastric pH of Japanese subjects stratified by IgG concentration against Helicobacter pylori and pepsinogen status.
Kishikawa H; Nishida J; Ichikawa H; Kaida S; Takarabe S; Matsukubo T; Miura S; Morishita T; Hibi T
Helicobacter; 2011 Dec; 16(6):427-33. PubMed ID: 22059393
[TBL] [Abstract][Full Text] [Related]
13. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
[TBL] [Abstract][Full Text] [Related]
14. Serological Evaluation of Gastric Cancer Risk Based on Pepsinogen and Helicobacter pylori Antibody: Relationship to Endoscopic Findings.
Kotachi T; Ito M; Yoshihara M; Boda T; Kiso M; Masuda K; Matsuo T; Tanaka S; Chayama K
Digestion; 2017; 95(4):314-318. PubMed ID: 28571035
[TBL] [Abstract][Full Text] [Related]
15. High-Negative Anti-
Inoue M; Sawada N; Goto A; Shimazu T; Yamaji T; Iwasaki M; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):420-426. PubMed ID: 31826914
[TBL] [Abstract][Full Text] [Related]
16. Receiver operating characteristic analysis of prediction for gastric cancer development using serum pepsinogen and Helicobacter pylori antibody tests.
Hamashima C; Sasazuki S; Inoue M; Tsugane S;
BMC Cancer; 2017 Mar; 17(1):183. PubMed ID: 28279154
[TBL] [Abstract][Full Text] [Related]
17. Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.
Bölükbaş C; Bölükbaş FF; Ovünç O; Kiliç G; Dalay R; Güven H; Uras F; Yardimci TK; Sökmen MH; Agan AF; Pişkinpaşa N
Turk J Gastroenterol; 2006 Sep; 17(3):172-6. PubMed ID: 16941249
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study.
Kiso M; Yoshihara M; Ito M; Inoue K; Kato K; Nakajima S; Mabe K; Kobayashi M; Uemura N; Yada T; Oka M; Kawai T; Boda T; Kotachi T; Masuda K; Tanaka S; Chayama K
Gastric Cancer; 2017 Sep; 20(5):764-771. PubMed ID: 28025702
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of group D patients with negative serum anti-Helicobacter pylori antibody and positive serum pepsinogen test in healthy Koreans.
Han YM; Chung SJ; Choi JM; Lee C; Kim JS
J Dig Dis; 2018 Sep; 19(9):529-539. PubMed ID: 30117281
[TBL] [Abstract][Full Text] [Related]
20. Usefulness and Limitations of a Serum Screening System to Predict the Risk of Gastric Cancer.
Kishino T; Oyama T; Tomori A; Takahashi A; Shinohara T
Intern Med; 2020 Jun; 59(12):1473-1480. PubMed ID: 32188803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
